- In February 2022, GlaxoSmithKline initiated a Phase III clinical trial to evaluate the safety and immune response of an unadjuvanted RSV maternal vaccine. The study focuses on healthy non-pregnant women aged 9 to 49 years. This investigation aims to assess the potential of the vaccine in preparing maternal immunity for the prevention of respiratory syncytial virus (RSV)
- In February 2021, GlaxoSmithKline began a Phase IV clinical trial to compare the safety and immunogenicity of MCM BV’s Vaxelis vaccine with its own Infanrix Hexa vaccine. The study targets healthy infants and toddlers aged 6 to 12 weeks. The goal is to assess the effectiveness and safety profiles of both vaccines when administered to young children
- In January 2021, Sanofi launched a Phase IV clinical trial in the Republic of South Africa to evaluate the immune response to booster vaccination with the Tdap-IPV vaccine, which protects against tetanus, diphtheria, pertussis, and poliomyelitis. The trial aims to assess the vaccine’s effectiveness in boosting immunity in individuals. This investigation is part of Sanofi's ongoing efforts to improve vaccination strategies and public health outcomes
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Whole-Cell Vaccines, Acellular Vaccines, and Others), Type (Azithromycin, Clarithromycin, Erythromycin, and Other), Diagnosis (Chest X-Ray, Blood Tests, and Others), Treatment (Medication, Vaccination, and Others), Medication (Antibiotics, Cough Suppressants, and Others), Route of Administration (Oral, Injectable, and Others), Application (Children and Adults), End Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others) – Industry Trends and Forecast to 2032
.
The Global Pertussis Treatment Market size was valued at USD 3.80 USD Billion in 2024.
The Global Pertussis Treatment Market is projected to grow at a CAGR of 6.4% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
